The clinical dilemma of high-risk stage II colon cancer: are we truly prepared to withdraw oxaliplatin?

Affiliations

¹ Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France. Electronic address: jtaieb75@gmail.com.
² Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy.
³ Division of Oncology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
⁴ Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France.

Editorial

J Taieb et al. ESMO Open. 2024 Dec.

. 2024 Dec;9(12):104072.

doi: 10.1016/j.esmoop.2024.104072. Epub 2024 Dec 2.

¹ Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France. Electronic address: jtaieb75@gmail.com.
² Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy.
³ Division of Oncology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
⁴ Institut du Cancer Paris CARPEM, AP-HP Centre, Department of Gastroenterology and Digestive Oncology, Hôpital Européen Georges Pompidou, Paris, France.

No abstract available

Cited by

Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset.
Daprà V, Gandini A, Schietroma F, Rossini D, Boccaccino A, Caira G, Calegari MA, Zoratto F, Costantini M, Formica V, Rofei M, Mauri G, Bonazzina E, Siena S, Iaia ML, Signorelli C, Antonuzzo L, Tamberi S, Foppa C, Spinelli A, Tortora G, Santoro A, Taieb J, Puccini A, Salvatore L. Daprà V, et al. ESMO Open. 2025 Aug;10(8):105496. doi: 10.1016/j.esmoop.2025.105496. Epub 2025 Jul 15. ESMO Open. 2025. PMID: 40669095 Free PMC article.

1. Chibaudel B., Raeisi M., Cohen R., et al. Assessment of the addition of oxaliplatin to fluoropyrimidine-based adjuvant chemotherapy in patients with high-risk stage II colon cancer: an ACCENT pooled analysis. J Clin Oncol. 2024 JCO.24.00394. - PMC - PubMed
1. André T., Boni C., Navarro M., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116. - PubMed
1. Kuebler J.P., Wieand H.S., O’Connell M.J., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–2204. - PubMed
1. André T., De Gramont A., Vernerey D., et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33(35):4176–4187. - PubMed
1. Argilés G., Tabernero J., Labianca R., et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–1305. - PubMed